12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Eisai sales and marketing update

Eisai launched Halaven eribulin mesylate in the U.K., Sweden, Denmark and Finland to treat locally advanced metastatic breast cancer in...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >